Sage Gets Fast-Track Designation for Huntington's Disease Treatment

 Sage Therapeutics Inc. said it has gotten a fast-track designation from the Food and Drug Administration for its Sage-718 drug candidate to be developed as potential treatment for Huntington's disease.

The fast track is a process for facilitating the development and review of new treatments for severe conditions.

Sage said it expects to start a Phase 2 trial with the drug candidate in early to moderate Huntington's disease in late 2021.

Huntington's disease is a rare, inherited neurodegenerative disease, Sage said. As many as 30,000 adults are diagnosed with the disease in the U.S. each year, the company said.

https://www.marketscreener.com/quote/stock/SAGE-THERAPEUTICS-INC-16917559/news/Sage-Therapeutics-Gets-Fast-Track-Designation-for-Huntington-s-Disease-Treatment-36430211/